CRVS - NASDAQ
Corvus Pharmaceuticals, Inc.
$11.78
+0.77%Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
At a Glance
Live Snapshotcrvs
Total Current Liabilities
Last Annual Value
9.38M
3-Year CAGR
-4%
5-Year CAGR
-5%
10-Year CAGR
12%
Corvus Pharmaceuticals, Inc. Competitors Analysis of Total Current Liabilities
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | 9.38M | 10.9% | -0.7% | 2.5% | |
 Absci Corporation NASDAQ:ABSI | 22.77M | -8.3% | -7.6% | N/A | |
 Gossamer Bio, Inc. NASDAQ:GOSS | 63.44M | 7.1% | 9.7% | 83.9% | |
 Verastem, Inc. NASDAQ:VSTM | 72.27M | 39.9% | 31.2% | 20.7% | |
 Ventyx Biosciences, Inc. NASDAQ:VTYX | 12.78M | -16.9% | 0.8% | N/A | |
 Compass Therapeutics, Inc. NASDAQ:CMPX | 13.97M | 21.4% | 5.6% | N/A | |
 Prothena Corporation plc NASDAQ:PRTA | 40.84M | -10.5% | 4.1% | -0.1% | |
 Olema Pharmaceuticals, Inc. NASDAQ:OLMA | 51.80M | 33.8% | 41.9% | N/A | |
 Akebia Therapeutics, Inc. NASDAQ:AKBA | 162.94M | 17.7% | -9.0% | 3.6% | |
 REGENXBIO Inc. NASDAQ:RGNX | 118.09M | -3.2% | -2.0% | 28.4% | |
 KalVista Pharmaceuticals, Inc. NASDAQ:KALV | 57.35M | 56.3% | 42.5% | 33.3% |
Corvus Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your CRVS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.